Analysis of Plk1-Bora interaction using a protein chip system

Biochip Journal

Volumn 7, Issue 2, 2013, Pages 151-155

  Lee, Jung kyu ^a   Kang, In Cheol ^a,b  

^a Hoseo University   (South Korea)

^b Innopharmascreen Inc   (South Korea)

Author keywords

Bora peptide; Plk1; Proteinprotein interaction; Proteochip ; Thymoquinone

Indexed keywords

CELL PROLIFERATION;

BINDING SYSTEMS; DOSE-DEPENDENT MANNER; FLUORESCENT DYES; PLK1; POLO-BOX DOMAIN; POLO-LIKE KINASE 1; PROTEIN-PROTEIN INTERACTIONS; THYMOQUINONE;

PEPTIDES;

BORA PEPTIDE; CELL PROTEIN; FLUORESCENT DYE; GLUTATHIONE TRANSFERASE; POLO LIKE KINASE 1; PROTEIN INHIBITOR; THYMOQUINONE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONJUGATION; CONTROLLED STUDY; ENZYME ANALYSIS; IN VITRO STUDY; LABORATORY DEVICE; LUNG CANCER; PROTEIN BINDING; PROTEIN CONJUGATION; PROTEIN DOMAIN; PROTEIN MICROARRAY; PROTEIN PROTEIN INTERACTION; SCREENING TEST;

EID: 84879707057     PISSN: 19760280     EISSN: 20927843     Source Type: Journal    
DOI: 10.1007/s13206-013-7208-6     Document Type: Article

References (13)

1. Lee, Y. et al. ProteoChip: A highly sensitive protein microarray prepared by a novel method of protein immobilization for application of protein-protein interaction studies. Proteomics. 3, 2289-2304 (2003).
2. Lee, Y. S., Han, M. H., Kang, D. K., Chang, S. I. & Kang, I. C. High-throughput screening of novel peptide inhibitors of an integrin receptor from the hexapeptide library by using a protein microarray chip. J. Biomolecular Screening9, 687-694 (2004).
3. Bang, J. Y. et al. Analysis of anti-angiogenic mechanism of HangAmDan-B(HAD-B), a Korean traditional medicine, using antibody microarray chip. Biochip J. 4, 350-355 (2010).
4. Strebhardt, K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat. Rev. Drug Discov. 9, 643-660 (2010).
5. Elia, A. E. et al. The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell115, 83-95 (2003).
6. Elia, A. E., Cantley, L. C. & Yaffe, M. B. Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. Science299, 1228-1231 (2003).
7. Eckerdt, F. & Maller, J. L. Kicking off the polo game. Trends Biochem. Sci. 33, 511-513 (2008).
8. Seki, A., Coppinger, J. A., Jang, C. Y., Yates, J. R., & Fang, G. Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science320, 1655-1658 (2008).
9. Lee, K. S. & Erikson, R. L. Plk is a functional homolog of Saccharomyces cerevisiae Cdc5, and elevated Plk activity induces multiple septation structures. Mol. Cell Biol. 17, 3408-3417 (1997).
10. Jang, Y. J., Lin, C. Y., Ma, S. & Erikson, R. L. Functional studies on the role of the C-terminal domain of mammalian polo-like kinase. Proc. Natl. Acad. Sci. USA99, 1984-1989 (2002).
11. Sasakura, Y. et al. Protein microarray system for detecting protein-protein interactions using an anti-His-tag antibody and fluorescence scanning: effects of the heme redox state on protein-protein interactions of heme-regulated phosphodiesterase from Escherichia coli. Anal. Chem. 76, 6521-6527 (2004).
12. Gali-Muhtasib, H., Roessner, A. & Schneider-Stock, R. Thymoquinone: a promising anti-cancer drug from natural sources. Int. J. Biochem. Cell Biol. 38, 1249-1253 (2006).
13. Kaseb, A. O. et al. Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res. 67, 7782-7788 (2007).